These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24711549)

  • 1. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
    Chien AJ; Munster PN; Melisko ME; Rugo HS; Park JW; Goga A; Auerback G; Khanafshar E; Ordovas K; Koch KM; Moasser MM
    J Clin Oncol; 2014 May; 32(14):1472-9. PubMed ID: 24711549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
    Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V
    Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
    Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
    Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel Plus Lapatinib as Therapy for HER2
    Yardley DA; Hart LL; Ward PJ; Wright GL; Shastry M; Finney L; DeBusk LM; Hainsworth JD
    Clin Breast Cancer; 2018 Oct; 18(5):e781-e787. PubMed ID: 29678476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
    Spector NL; Robertson FC; Bacus S; Blackwell K; Smith DA; Glenn K; Cartee L; Harris J; Kimbrough CL; Gittelman M; Avisar E; Beitsch P; Koch KM
    PLoS One; 2015; 10(11):e0142845. PubMed ID: 26571496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
    Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
    Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Rocca A; Cecconetto L; Passardi A; Melegari E; Andreis D; Monti M; Maltoni R; Sarti S; Pietri E; Schirone A; Fabbri F; Donati C; Nanni O; Fedeli A; Faedi M; Amadori D
    Cancer Chemother Pharmacol; 2017 May; 79(5):863-871. PubMed ID: 28341957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
    Falchook GS; Moulder SL; Wheler JJ; Jiang Y; Bastida CC; Kurzrock R
    Ann Oncol; 2013 Dec; 24(12):3004-11. PubMed ID: 24158411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
    Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
    J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
    Kimple RJ; Horton JK; Livasy CA; Shields JM; Lawrence JA; Chiu WM; Ivanova A; Ollila DW; Carey LA; Halle JS; Sartor CI; Dees EC
    Oncologist; 2012; 17(12):1496-503. PubMed ID: 23006498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
    Brain E; Isambert N; Dalenc F; Diéras V; Bonneterre J; Rezai K; Jimenez M; Mefti-Lacheraf F; Cottura E; Tresca P; Vanlemmens L; Mahier-Aït Oukhatar C; Lokiec F; Fumoleau P
    Br J Cancer; 2012 Feb; 106(4):673-7. PubMed ID: 22240778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
    Chia SK; Ellard SL; Mates M; Welch S; Mihalcioiu C; Miller WH; Gelmon K; Lohrisch C; Kumar V; Taylor S; Hagerman L; Goodwin R; Wang T; Sakashita S; Tsao MS; Eisenhauer E; Bradbury P
    Breast Cancer Res; 2017 May; 19(1):54. PubMed ID: 28464908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer.
    Zhang T; Li Q; Chen S; Luo Y; Fan Y; Xu B
    Oncotarget; 2017 May; 8(22):36750-36760. PubMed ID: 27902470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.